Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples

Source: Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma
In this podcast episode, listen to Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss management of patients with multiple myeloma from a recent symposium during the annual hematology meeting in 2021.
Brian G.M. Durie, MD
Thomas G. Martin, MD
Philippe Moreau, MD
S. Vincent Rajkumar, MD
Jesus San-Miguel, MD, PhD
Released: February 18, 2022

In this episode, Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases.

  • Smoldering myeloma
  • Induction therapy for autologous stem cell transplant–eligible patients
  • First-line approaches for autologous stem cell transplant–ineligible patients
  • Treatment after first relapse
  • Selecting therapy for heavily pretreated myeloma

Information on this Educational Activity

Faculty

Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda and fees for non-CME/CE services from Amgen.
Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received funds for research support from Amgen, Johnson & Johnson/Janssen, Sanofi, and Seattle Genetics and consulting funds from GlaxoSmithKline and Oncopeptides.
Philippe Moreau, MD

Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, Oncopeptides, and Sanofi.
S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

S. Vincent Rajkumar, MD, has no relevant conflicts of interest to report.
Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio, and Takeda.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Oncopeptides
Pfizer, Inc.
Sanofi Genzyme

Related Content

Experts highlight key studies being presented at the 2022 ASH Annual Meeting in this commentary from Clinical Care Options (CCO)

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC person default David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Adolfo de la Fuente Burguera, MD
Program Director Claudio Cerchione, MD, PhD Naval G. Daver, MD person default Pau Montesinos, MD, PhD Eytan M. Stein, MD Released: December 1, 2022

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings